Table 5.
Selected examples of NTD inventions patented by FIOCRUZ, Brazil
| Disease targeted | Invention use | Invention type | Patent description | Date published |
|---|---|---|---|---|
| Chagas | Diagnostic | Compounds | Antigens and synthetic polypeptides for use in diagnosing Chagas | 1991 |
| Chagas | Therapeutic | Compounds | Synergistic antagonists used in combined therapy with prio-oxidizing drugs, specifically benznidazole | 2010 |
| Chagas | Therapeutic | Compounds | Pharmaceutical compositions for detecting and controlling tricatoms, the vectors of Chagas disease | 2005 |
| Chagas | Therapeutic | Compounds | Lentinus strigosus extracts and pharmaceutical compositions used for the inhibition of cancer tumors and Chagas disease | 2008 |
| Chagas | Diagnostic | Method and compounds | Method kit for the detection of T. cruzi in saliva | 2001 |
| Infectious diseases | Diagnostic | Method and compounds | Process of preparing antigen compositions for the use in diagnosing infectious diseases | 1992 |
| Infectious diseases | Therapeutic | Compounds | Compounds for treatment or prevention of infectious diseases | 2008 |
| Leishmaniasis | Therapeutic | Compounds | Polypeptides for use in the treatment of leishmaniasis | 2006 |
| Leishmaniasis | Diagnostic | Compounds | Use of recombinant leishmania antigens in detecting, identifying, and qualifying specific antibodies in biological material to be used for the diagnosis of leishmaniasis and further uses (treatment, vaccines) | 2010 |
| Leishmaniasis | Therapeutic | Compounds | Vinca alkaloid extracts used for treating leishmaniasis | 2000 |
| Leishmaniasis | Therapeutic | Compounds | Metabolites and inhibitors of leishmaniasis | 2009 |
| Leishmaniasis | Therapeutic | Compounds | Process of obtaining compounds and derivatives for the treatment of leishmaniasis | 2008 |
| Leishmaniasis | Diagnostic therapeutic | Method | Process for preparing antigens for diagnosis of and vaccination for cutaneous and visceral leishmaniasis | 1990 |
| Leishmaniasis | Therapeutic | Compounds | Pharmaceutical composition containing alagoa red propolis extract in combination with injectable meglumine antimoniate for treating tetanus leishmaniasis | 2017 |
| Leishmaniasis | Diagnostic | Method and compounds | Molecular differentiation of leishmania species | 2002 |
| Malaria | Diagnostic | Compounds | Plasmodium gallinaceum antigens for use in the diagnosis of malaria | 2001 |
| Malaria | Therapeutic | Compounds | Antimalarial composition using a combination of natural polyphenol curcumin and sodium diethyldithiocarbamate for the treatment of malaria | 2018 |
| Malaria | Therapeutic | Compounds | Compounds derived from artesunate for the treatment of parasitic diseases such as malaria | 2005 |
| Tuberculosis | Diagnostic | Vaccine compounds | Recombinant. Mycobacterium proteins for the diagnosis of tuberculosis and a tuberculosis vaccine | 2015 |
| Tuberculosis | Therapeutic | Compounds | Pharmaceutical composition for the treatment of tuberculosis | 2017 |
| Tuberculosis | Therapeutic | Compounds | A-ketoacyl compounds used to develop new derivatives of isoniazid for the treatment of tuberculosis | 2016 |
| Tuberculosis | Therapeutic | Compounds | Azole compounds used as tuberculostatic and leishmanicidal agents and pharma compositions | 2007 |
Source Authors elaboration from the original dataset